



Northern Treatment
Advisory Group

Northern (NHS) Treatment Advisory Group

Treatment Appraisal: Decision Summary

Date	9 th September 2014 (reviewed 22 nd February 2022)
Appraisal & Details	Ulipristal (EllaOne®) for post-coital contraception: Updated data concerning the effect of body weight (BMI) on efficacy of both Levonorgestrel and Ulipristal products.
Recommendation	Ulipristal (EllaOne®) is recommended as a treatment option as per the current Faculty of Sexual & Reproductive Healthcare (FSRH) Emergency Contraception Guidelines available at: https://www.fsrh.org/standards-and-guidance/documents/ceu-clinical-guidance-emergency-contraception-march-2017/
Clinical evidence summary	The group acknowledged that, with full publication of the clinical data, the efficacy and safety of Ulipristal for post-coital contraception had been adequately demonstrated. Following the publication of the post-hoc analyses of the combined data set in patients with high BMI the group supported the EMA stance and considered this data to be methodologically weak. It was therefore felt that the previous recommendation should remain.
Safety	The safety of Ulipristal for post-coital contraception had been adequately demonstrated in clinical trials. The EU wide review assessed whether bodyweight affects the effectiveness of Ulipristal (and Levonorgestrel) and stated that <i>the data are too limited and not robust enough to conclude with certainty that contraceptive effect is reduced with increased body weight.</i>
Patient Perspective	Previous changes in commissioning arrangements for emergency contraception have greatly improved access for patients. Convenience, flexibility and timeliness are likely to be valued by women and may contribute to greater overall effectiveness. Data suggests that only a very small number of women opt for intra-uterine devices despite being counselled about greater efficacy. Many women are likely to prefer the convenience and simplicity of oral methods.
Cost analysis summary	The group noted the substantial relative cost differential between Ulipristal and Levonorgestrel. However the total budget impact from a shift in prescribing policy towards Ulipristal would be limited by the modest overall treatment volumes.
Financial impact PbR: In-tariff	The cost per dose of Ulipristal is about £14 compared with about £6 for Levonorgestrel 1.5 mg. No significant cost impact is expected.